A man walks into an office and says he is having trouble in the bedroom. Fifteen minutes later he walks out with a prescription. A woman walks in and says something is off, or this pain is not normal, and a lot of the time she walks out with a suggestion to see a therapist or manage her stress.

Same building. Same kind of complaint. Very different response. Dr. Siân West, board-certified OB-GYN and menopause specialist, walks through what the research actually shows.

Sildenafil, the drug we know as Viagra, was approved by the FDA in 1998 after roughly a six-month priority review. The first approved drug for low sexual desire in women, flibanserin, did not arrive until 2015. Seventeen years later, and only after being rejected twice.

This episode puts both drugs side by side, which almost nobody does. Viagra worked well in its trials, taking men from about 1.5 successful attempts a month to about 5.9. Flibanserin worked modestly, about half an additional satisfying event a month. But the reason those numbers differ is the point. Blood flow had been studied for decades. Female sexual desire had almost no foundational science behind it, so the drug that finally arrived had almost nothing to build on.

The safety comparison runs the other way. Flibanserin carries a boxed warning, for low blood pressure and fainting. Viagra has never carried one, despite a nitrate contraindication that can be fatal, sudden permanent vision loss, sudden hearing loss, and priapism that can cause permanent damage. 128 deaths were reported in association with Viagra in its first eight months on the US market. The FDA strengthened the label wording. The drug stayed on the market and kept its six-month approval.

The pattern does not stop at which drugs get made. A 2024 study of nearly twenty two thousand emergency department records in the United States and Israel found women were less likely to be given pain medication than men at every pain score and in every age group, and their pain score was ten percent less likely to be recorded by the triage nurse at all. The same bias appeared with male and female clinicians alike.

Research on nearly four hundred thousand heart attack admissions in the nineteen nineties found women under fifty died in hospital at more than twice the rate of men the same age. Separate work on patients fifty and under found young women were less likely to be discharged on the right medications, and less likely to have had their arteries looked at.

The root of it: until 1993, FDA policy kept women of childbearing age out of early-stage drug trials in the United States. Decades of foundational work on pain, drug response and basic physiology was built on a study population that skewed heavily male, and then applied to everyone.

In this episode:

- The approval timeline, and the thirty-year head start sitting behind it

- The side by side almost nobody runs: what each drug does, and what each one is allowed to do to you

- What the 2024 pain study found at every single pain score, and whose pain gets written down at all

- Why "women just report more pain" does not explain the gap

- The exact sentence to use when a physical symptom gets blamed on stress: I would like this looked at as a physical symptom first

- How to ask what specifically is being ruled out, and how

- Why a second opinion is not dramatic

This is not an argument that individual clinicians are careless. Most people in medicine are trying, inside a system trained on incomplete information. The pattern is still real, and still measurable.